


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1-13. (canceled).

14. (currently amended): ~~The method as described in claim 9A~~ a method for promoting hair growth in a mammalian subject, comprising administering a composition comprising an effective amount of a prostaglandin compound having two hetero atoms at the 15 position to the subject in need thereof, wherein said prostaglandin compound is the compound as shown by the following formula (I):



wherein L, M and N are hydrogen, hydroxy, halogen, lower alkyl, hydroxy(lower)alkyl, lower alkanoyloxy or oxo, wherein at least one of L and M is a group other than hydrogen, and the five-membered ring may have at least one double bond;

A is -CH₃, or -CH₂OH, -COCH₂OH, -COOH or a functional derivative thereof;

B is -CH₂-CH₂-, -CH=CH- or -C≡C-;


Z_1 and Z_2 are oxygen, nitrogen or sulfur;

R_2 and R_3 are optionally substituted lower alkyl, which is optionally linked together to form lower alkylene;

R_1 is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, alkyl, hydroxy, oxo, aryl or heterocyclic group, and at least one of carbon atom in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur; and

R_a is a saturated or unsaturated lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, oxo, hydroxy, lower alkoxy, or lower alkanoyloxy; ~~cyclo(lower)alkyl, cyclo(lower)alkyloxy, aryl, aryloxy, heterocyclic group or heterocyclic-oxy group; lower alkoxy; or lower alkanoyloxy; cyclo(lower)alkyl; cyclo(lower)alkyloxy; aryl; aryloxy; heterocyclic group; or heterocyclic-oxy group.~~

15. (currently amended): The method as described in claim 14, wherein the prostaglandin compound is represented by the formula (II):



wherein L, M, A, B, Z_1 , Z_2 , R_1 , R_2 and R_3 are the same as in Claim 14,

X₁ and X₂ are hydrogen, lower alkyl, or halogen;

R₄ is a single bond or lower alkylene; and

R₅ is lower alkyl, lower alkoxy, or lower alkanoyloxy, ~~cyclo(lower)alkyl,~~
~~cyclo(lower)alkyloxy, aryl, aryloxy, heterocyclic group or heterocyclic-oxy group.~~

16. (currently amended): The method as described in ~~claim 9~~ claim 14, wherein said prostaglandin compound is 13,14-dihydro-15,15-ethylenedioxy-20-ethyl-PGF_{2α} isopropyl ester.

17. (canceled).

18. (withdrawn-currently amended): The method as described in ~~claim 9~~ claim 14, wherein said prostaglandin compound is 13,14-dihydro-15,15-trimethylenedioxy-20-ethyl-PGF_{2α} isopropyl ester.

19. (withdrawn-currently amended): The method as described in ~~claim 9~~ claim 14, wherein said prostaglandin compound is 13,14-dihydro-15,15-dimethoxy-20-ethyl-PGF_{2α} isopropyl ester.

20. (withdrawn-currently amended): The method as described in ~~claim 9~~ claim 14, wherein said prostaglandin compound is 13,14-dihydro-15,15-ethylenedioxy-20-ethyl-PGF_{2α} ethyl ester.

21. (currently amended): The method as described in ~~Claim 9~~ claim 14, wherein the hair is selected from hair on top of head, hair on armpits, hair on pubic area, eyelash, eyebrow, hair on eyelid, mustache, beard, whisker, hair on chest, hair on arms and hair on legs.

22. (currently amended): The method as described in ~~Claim 9~~ claim 14, wherein the hair is selected from hair on scalp, beard, hair on head, hair on pubic area, hair on upper lip, eyelash, eyebrow, and hair on eyelid.

23. (currently amended): The method as described in ~~Claim 9~~ claim 14, wherein the hair is hair on scalp.

24. (currently amended): The method as described in ~~Claim 9~~ claim 14, wherein the hair is eyelash.

25. (new): The method as described in claim 14, wherein the prostaglandin compound of formula (I) is present in the composition in a concentration of 0.001-0.1%.

26. (new): The method as described in claim 24, wherein the prostaglandin compound of formula (I) is present in the composition in a concentration of 0.001-0.1%.

27. (new): The method as described in claim 24, wherein said prostaglandin compound is 13,14-dihydro-15,15-ethylenedioxy-20-ethyl-PGF_{2α} isopropyl ester.

28. (new): The method as described in claim 24, wherein said prostaglandin compound is 13,14-dihydro-15,15-ethylenedioxy-20-ethyl-PGF_{2α} isopropyl ester, which is present in the composition in a concentration of 0.001-0.1%.